Why is Suven Life Scie. falling/rising?

Recent Price Movement and Market Performance

Suven Life Sciences has experienced a sustained downward trend over the past week, with the stock falling 6.69% compared to a marginal 0.06% decline in the Sensex benchmark. Over the last month, the stock’s decline has been even more pronounced at 15.43%, while the Sensex gained 0.82%. Despite these short-term setbacks, the stock has delivered strong returns over longer periods, with a year-to-date gain of 31.17% and a one-year return of 43.80%, significantly outperforming the Sensex’s 8.65% and 7.31% respectively. The three- and five-year returns are also impressive, at 156.65% and 253.40%, well above the benchmark’s 36.34% and 90.69%.

However, the recent price action is concerning. The stock has declined for three consecutive days, losing 6.35% in that period. Intraday lows touched ₹168, representing a 4.33% drop on the day, with heavier trading volume concentrated near these lower price levels. The weighted average price indicates that sellers dominated the session, pushing prices downwards. Furthermore, Suven Life Sciences is trading below all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling bearish technical momentum.

Investor participation has increased, with delivery volumes rising by nearly 52% on 21 Nov compared to the five-day average, suggesting heightened activity but not necessarily positive sentiment. Liquidity remains adequate for moderate trade sizes, but the prevailing trend is clearly negative.

Fundamental Challenges Weighing on the Stock

Despite the stock’s strong historical returns, Suven Life Sciences faces significant fundamental headwinds that explain the recent price weakness. The company has reported operating losses and weak long-term growth metrics. Over the past five years, net sales have declined at an annualised rate of 23.11%, while operating profit has contracted sharply by 186.11% annually. This deterioration in core business performance undermines investor confidence in the company’s growth prospects.

The company’s ability to service debt is also poor, with an average EBIT to interest ratio of -149.78, indicating that earnings before interest and taxes are insufficient to cover interest expenses. This financial strain is compounded by five consecutive quarters of negative results. The latest quarterly profit after tax (PAT) stood at a loss of ₹77.31 crores, a steep 67.9% decline compared to the average of the previous four quarters.

Operating cash flow for the year is at a low of ₹-47.39 crores, and cash and cash equivalents at half-year are also at a minimal ₹10.79 crores. These figures highlight liquidity concerns and operational inefficiencies that contribute to the stock’s risk profile. The company’s negative EBITDA further emphasises the precarious financial position, making the stock riskier relative to its historical valuations.

While institutional investors have increased their stake by 0.59% over the previous quarter, collectively holding 4.56%, their participation has not been sufficient to offset the negative sentiment driven by weak fundamentals and recent losses. Institutional investors typically have greater resources to analyse company fundamentals, and their cautious stance may reflect concerns about the company’s financial health.

Balancing Past Performance with Present Risks

Suven Life Sciences’ stock performance over the past three to five years has been exceptional, outpacing the broader market by a wide margin. However, the recent decline highlights the risks associated with the company’s deteriorating operational results and financial health. The disconnect between strong stock returns and falling profits—down 45.2% over the past year—suggests that investors are increasingly wary of the sustainability of gains amid ongoing losses.

In summary, the stock’s fall on 24-Nov and the preceding days can be attributed to a combination of weak quarterly results, poor long-term growth trends, negative cash flows, and technical indicators signalling bearish momentum. While institutional interest remains, it has not been enough to counterbalance the negative fundamentals and market sentiment. Investors should weigh these factors carefully when considering exposure to Suven Life Sciences.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →